Vasopressin

Vasopressin (Arginine Vasopressin, AVP)

Pharmacologic Class

  • Endogenous antidiuretic hormone (ADH)
  • Vasopressor; antidiuretic

Common Brand Names

  • Pitressin® (IV, IM, SQ)
  • Vasostrict® (IV – commonly used in ICU)

Mechanism of Action (Receptor-Specific)

 

Vasopressin exerts effects via three major receptors

advanced receptor-level diagram of vasopressin mechanism of action: show V1a receptor on vascular smooth muscle activating Gq protein, leading to phospholipase C activation, IP3/DAG production, calcium release, and vasoconstriction; show V2 receptor on renal collecting duct activating Gs protein, leading to adenylyl cyclase activation, cAMP increase, PKA activation, aquaporin-2 insertion, and water reabsorption; include labeled arrows, receptor types, and cell types in a clean medical illustration style

Receptor Location Clinical Effect
V1a Vascular smooth muscle Potent vasoconstriction → ↑ SVR, ↑ MAP
V2 Renal collecting ducts ↑ Aquaporin-2 insertion → water reabsorption
V1b (V3) Pituitary ↑ ACTH release (minor clinical role)

V1 Receptor Pathway — Hemodynamic Effects

Location: Vascular smooth muscle Receptor type: V1a (Gq‑coupled)

What happens:

  • Activation of Gq protein
  • ↑ Phospholipase C → ↑ IP₃ and DAG
  • ↑ Intracellular Ca²⁺
  • Potent vasoconstriction

Why pharmacists care:

  • Restores MAP in vasodilatory shock (e.g., septic shock)
  • Useful when catecholamines are insufficient
  • Minimal effect on heart rate, so helpful in tachyarrhythmias
  • Risk: ischemia (gut, skin, extremities) at higher doses

V2 Receptor Pathway — Renal Water Conservation

Location: Renal collecting duct principal cells Receptor type: V2 (Gs‑coupled)

What happens:

  • Activation of Gs protein
  • ↑ cAMP → ↑ PKA
  • Insertion of aquaporin‑2 channels into the apical membrane
  • ↑ Free water reabsorption
  • ↓ Urine output, ↑ Urine osmolality

Why pharmacists care:

  • Treatment of central diabetes insipidus
  • Adjunct in variceal bleeding (via V1 effects)
  • Risk: hyponatremia if water intake is not controlled

V1 vs V2: Quick Comparison

Feature V1 (Vascular) V2 (Renal)
Receptor Gq‑coupled Gs‑coupled
Location Vascular smooth muscle Collecting duct
Main effect Vasoconstriction Water reabsorption
Clinical use Shock, variceal bleeding DI, perioperative UOP control
Key risk Ischemia Hyponatremia

Clinical Pearls for Pharmacists

  • Vasopressin is not titrated like norepinephrine; typically fixed‑dose infusion.
  • Works synergistically with catecholamines by restoring vascular responsiveness.
  • In shock, its benefit is pressor support, not fluid retention.
  • Monitor: MAP, skin perfusion, serum sodium, urine output.

Key ICU concept:

  • Vasopressin increases MAP independently of adrenergic receptors, making it effective in catecholamine-refractory shock.

Indications (Hospital-Based)

1. Septic Shock (Adjunct Vasopressor)

  • Used in addition to norepinephrine
  • Particularly helpful in:
    • Refractory hypotension
    • Patients with relative vasopressin deficiency (late septic shock)

2. Vasodilatory Shock

  • Post-cardiac surgery
  • Liver transplant–related vasoplegia
  • Anesthesia-induced hypotension

3. Diabetes Insipidus (Central)

  • IV formulation in ICU
  • Often transitioned to desmopressin when stable

4. Variceal GI Bleeding (less common now)

  • Reduces portal venous pressure
  • Usually replaced by octreotide due to safety profile

5. Cardiac Arrest (ACLS – historical/limited)

  • No longer preferred over epinephrine
  • Still encountered in some protocols or older order sets

Dosing (Critical for Pharmacists)

Septic Shock / Vasodilatory Shock

  • Fixed dose: 0.03 units/min IV infusion
  • May increase to 0.04 units/min (max)
  • No titration based on BP (unlike norepinephrine)
  • Do NOT exceed 0.04 units/min → ↑ ischemic risk

⚠️ Higher doses = ↑ risk of mesenteric, digital, and cardiac ischemia

Central Diabetes Insipidus (IV)

  • 0.5–2 units IV q2–4h PRN
  • Continuous infusion sometimes used (institution-specific)
  • Monitor serum sodium closely

Pharmacokinetics

  • Onset: Immediate (IV)
  • Half-life: ~10–20 minutes
  • Metabolism: Hepatic and renal vasopressinases
  • Elimination: Renal

Advantages vs Catecholamines

  • Works in acidotic states
  • No tachyarrhythmia
  • Reduces norepinephrine requirements (catecholamine-sparing)
  • Preserves renal perfusion in septic shock (theoretical benefit)

Adverse Effects (High-Yield for Monitoring)

  • Digital ischemia
  • Mesenteric ischemia
  • Myocardial ischemia
  • Skin necrosis (especially with peripheral lines)

Electrolyte / Fluid Effects

  • Hyponatremia (V2-mediated water retention)
  • Decreased urine output

Other

  • Abdominal cramping
  • Nausea
  • Headache
  • Rare: Rhabdomyolysis

Monitoring Parameters (Pharmacist-Driven)

Parameter Rationale
MAP & BP Efficacy
Lactate Tissue perfusion
Urine output Renal response
Serum sodium Hyponatremia risk
Signs of ischemia Fingers, toes, gut
Norepinephrine dose Weaning strategy

Drug Interactions & Clinical Pearls

  • Corticosteroids: Synergistic effect (common in septic shock bundles)
  • Loop diuretics: May blunt antidiuretic effect
  • Peripheral IV use: Avoid if possible → central line preferred
  • Weaning: Vasopressin is often stopped last or second-last

Special Populations

  • Renal impairment: No dose adjustment, but ↑ risk of hyponatremia
  • Cardiac ischemia: Use cautiously
  • Pregnancy: Category C; oxytocic effects possible

Comparison: Vasopressin vs Norepinephrine

Feature Vasopressin Norepinephrine
Receptor V1a α1, β1
Tachycardia No Possible
Titration Fixed Titrated
First-line No Yes
Ischemia risk High at ↑ doses Moderate

Key Clinical Takeaways for Pharmacists

  • Adjunct, not first-line, in septic shock
  • Use fixed low dose only
  • Watch for ischemia and hyponatremia
  • Valuable in catecholamine-refractory hypotension
  • Often part of ICU shock bundles
Tags: ,